03/20/23 9:00 AMNYSE : TAK clinical trialPhase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual MeetingResults from the Phase 2 b clinical trial of TAK-279, a novel allosteric TYK2 inhibitor developed by Nimbus Therapeutics and owned by Takeda, in patients with moderate-to-severe plaque psoriasis were presented on Saturday, March 18, 2023 at the 2023 American Academy of Dermatology Annual Meeting in New Orleans. The results were presented as part of the...RHEA-AIvery positive
03/18/23 7:00 AMNYSE : TAK clinical trialTakeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque PsoriasisTakeda today announced positive results from a Phase 2 b clinical trial of TAK-279, a highly selective, oral allosteric tyrosine kinase 2 inhibitor, in patients with moderate-to-severe plaque psoriasis. The study met its primary and secondary endpoints, with a statistically significant greater proportion of TAK-279 patients...RHEA-AIpositive
03/01/23 8:30 AMNYSE, Nasdaq : HASI, TAK, MNTS managementHannon Armstrong Appoints Former EXIM Chairman Kimberly A. Reed and CEO Jeffrey A. Lipson to Board of DirectorsHannon Armstrong Sustainable Infrastructure Capital, Inc., a leading investor in climate solutions, today announced the appointment of Kimberly A. Reed and Jeffrey A. Lipson to its Board of Directors, effective March 1, 2023. Ms. Reed said,“ Hannon Armstrong Sustainable Infrastructure Capital, Inc.— the very first U.S. public company to focus solely on...RHEA-AIvery positive
02/18/23 5:30 PMNYSE : TAK clinical trialTakeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT (p No New Safety Signals Were Seen with Vedolizumab Compared with Placebo in Patients Who Received Allo-HSCT Data Were Presented as A Late-Breaking Abstract at The 2023...RHEA-AIneutral
02/08/23 6:30 PMNYSE : TAK acquisitionTakeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program SubsidiaryTakeda today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. from Nimbus Therapeutics, LLC, on February 8, 2023, as set forth in the share purchase agreement, following clearance from the United States Federal Trade Commission and a satisfaction of other closing conditions.RHEA-AIneutral
02/08/23 6:30 PMNYSE : TAK acquisitionNimbus Therapeutics Announces Closing of Takeda’s Acquisition of TYK2 SubsidiaryNimbus Therapeutics, LLC, a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced the closing of Takeda’ s acquisition of Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus, and its tyrosine kinase 2 inhibitor program, which includes the oral, selective...RHEA-AIneutral
02/03/23 6:48 PMNYSE : TAK fda approvalU.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and OlderTAKHZYRO is the First and Only Prophylaxis Treatment Approved in the U.S. for Children 2 to 1-4 Approval Supported by Extrapolation of Efficacy Data From the Phase 3 HELP Study With Additional Data From the Phase 3 SPRING Study in Pediatric Patients 2 to 1 HAE is a Rare, Debilitating and Potentially Life-Threatening Condition That Causes Unpredictable and...RHEA-AIneutral
02/02/23 1:00 AMNYSE : TAK acquisitionTakeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3LIVTENCITY™ continues to generate high interest and strong uptake since its launch in the U.S. in December 2021, with 87% of U.S. transplant centers having initiated therapy with at least one patient. Plasma-Derived Therapies Immunology, with 502.4 billion yen in reported revenue, delivered outstanding growth of +18% on a CER basis. Growth was driven by higher...RHEA-AIpositive
01/23/23 3:00 AMNYSE, Nasdaq : TAK, HCM acquisitionTakeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase InhibitorTakeda today announced that it has entered into an exclusive licensing agreement with HUTCHMED Limited and its subsidiary HUTCHMED Limited, for the further development and commercialization of fruquintinib outside of mainland China, Hong Kong and Macau. Working with HUTCHMED will enable us to expand our oncology portfolio,...RHEA-AIvery positive
01/16/23 11:00 PMNYSE : TAK Takeda Named Global Top Employer for Sixth Consecutive Year−Achieved Global Recognition and Top Employer Certification in 22 Countries from Top Employers Institute. “We are steadfast in our commitment to creating a culture that fosters collaboration, well-being and resilience, and this recognition as a global top employer by the Top Employers Institute further underscores that focus,” said Lauren Duprey, chief...RHEA-AIvery positive